EUVIMEDEUVIMED entdecken
Crossref

Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria

Makoto Naganuma, Naohiro Nakamura, Reiko Kunisaki, Katsuyoshi Matsuoka, Shojiro Yamamoto, Ami Kawamoto, Daisuke Saito, Taku Kobayashi, Kosaku Nanki, Kazuyuki Narimatsu, Hisashi Shiga, Motohiro Esaki und 16 weitere

Journal of Gastroenterology · 2024

DOI: 10.1007/s00535-024-02079-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology, 2024. Verfasst von Makoto Naganuma und 27 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka, 573-…. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: the Japan Agency for Medical Research and Development, Health and Labour Sciences Research Grants for research on intractable diseases from the Ministry of Health, Labour and Welfare of Japan..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Hospitalization for ulcerative colitis (UC) is potentially life-threatening. Severe disease in the Japanese criteria which modifies the Truelove-Witts' criteria might encompass more fulminant cases than the definition for acute severe UC. However, few studies have investigated the predictive factors for clinical remission (CR) after medical treatments for severe hospitalized patients by Japanese criteria. METHODS: Medical treatment selection, CR rates, and factors contributing to CR on day 14 were assessed in severe patients by Japanese criteria. We also investigated whether the reduction rate in patient-reported outcome 2 (PRO2) on day 3 could predict short-term prognosis. RESULTS: Eighty-five severe hospitalized patients were selected. Corticosteroids, tacrolimus, and infliximab were mainly selected as first-line treatments (76/85; 89.4%). The CR rates on day 14 were 26.8%, 21.4%, and 33.3% in patients receiving corticosteroids, tacrolimus, and infliximab, respectively. Extensive disease (odds ratio [OR] 0.022; 95% confidence interval [CI] 0.002-0.198), higher PRO2 (OR 0.306; 95% CI 0.144-0.821), and higher reduction rate in PRO2 on day 3 (OR 1.047; 95% CI 1.019-1.075) were independent factors predicting CR on day 14. If the cutoff value for the reduction rate in PRO2 on day 3 was 18.3%, sensitivity was 0.714 and specificity was 0.731 to predict CR on day 14. A higher reduction rate in PRO2 on day 3 (OR 0.922; 95% CI 0.853-0.995) was a negative factor to predict surgery within 28 days. CONCLUSIONS: Tacrolimus and infliximab in addition to corticosteroids were used as first-line treatment in severe hospitalized patients. PRO2 on day 3 is a useful marker for switching to second-line therapy or colectomy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeHumansInfliximabImmunosuppressive AgentsTacrolimusJapanAdrenal Cortex HormonesTreatment OutcomeColectomyRetrospective Studies

Stichwörter der Autor:innen

CorticosteroidsHospitalized patientPatient-reported outcomeUlcerative colitis

Substanzen

InfliximabImmunosuppressive AgentsTacrolimusAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka, 573-1010, Japan. naganuma@hirakata.kmu.ac.jp.
  • Division of Gastroenterology and Hepatology, Third Department of Internal Medicine, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka, 573-1010, Japan.
  • Inflammatory Bowel Disease Center, Yokohama City University Medical Center, Yokohama, Japan.
  • Department of Gastroenterology, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
  • Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.

Förderung

  • the Japan Agency for Medical Research and Development
  • Health and Labour Sciences Research Grants for research on intractable diseases from the Ministry of Health, Labour and Welfare of Japan.

Zitieren

APA

Naganuma, M., Nakamura, N., Kunisaki, R., Matsuoka, K., Yamamoto, S., Kawamoto, A., Saito, D., Kobayashi, T., Nanki, K., Narimatsu, K., Shiga, H., Esaki, M., Yoshioka, S., Kato, S., Saruta, M., Tanaka, S., Yasutomi, E., Yokoyama, K., Moriya, K., …, & Japanese UC Study Group (2024). Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria. Journal of Gastroenterology. https://doi.org/10.1007/s00535-024-02079-x

Vancouver

Naganuma M, Nakamura N, Kunisaki R, Matsuoka K, Yamamoto S, Kawamoto A, et al. Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria. Journal of Gastroenterology. 2024. doi:10.1007/s00535-024-02079-x

BibTeX
@article{Naganuma2024,
  author = {Naganuma, Makoto and Nakamura, Naohiro and Kunisaki, Reiko and Matsuoka, Katsuyoshi and Yamamoto, Shojiro and Kawamoto, Ami and Saito, Daisuke and Kobayashi, Taku and Nanki, Kosaku and Narimatsu, Kazuyuki and Shiga, Hisashi and Esaki, Motohiro and Yoshioka, Shinichiro and Kato, Shingo and Saruta, Masayuki and Tanaka, Shinji and Yasutomi, Eriko and Yokoyama, Kaoru and Moriya, Kei and Tsuzuki, Yoshikazu and Ooi, Makoto and Fujiya, Mikihiro and Nakazawa, Atsushi and Takagi, Tomohisa and Omori, Teppei and Tahara, Toshiyuki and Hisamatsu, Tadakazu and Japanese UC Study Group, Japanese UC Study Group},
  title = {Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria},
  journal = {Journal of Gastroenterology},
  year = {2024},
  doi = {10.1007/s00535-024-02079-x}
}
Kostenlos starten →